Boehringer and Epizyme enter US$300m deal
Boehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Breakthrough in restless legs syndrome
Researchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome.
SOBI and AstraZeneca in US$2bn+ deal on RSV antibodies
AstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish Orphan Biovitrum AB.
Amal bags €21.2m financing
Swiss Amal Therapeutics S.A. (Geneva) has raised €21.2m in a series B follow-up financing.
Antibiotic resistance spreading across Europe
Antimicrobial resistance (AMR) has increased by 32% since 2007 in Europe, according to a brand new report.
Liquid biopsy: size matters
A new method developed by Swiss, Danish and British researchers allows to detect hard-to-trace tumour-derived DNA in the blood (or ctDNA).
Themis postpones IPO
One week after Austrian vaccine and cancer immunotherapy specialist Bioscience announced the terms of its initial public offering (IPO) and listing on Euronext Amsterdam, the company has postponed its IPO.
CARs right on track
Since reports that blood cancer response rates to T cells carrying chimeric antigen receptors (CARs) exceed 80%, investors have been laying bets on CAR-T cell approaches. In August, the first two therapies hit European markets in a head-to-head race to be the number one next-gen cancer therapy. So will CAR-T cell treatment really take pole position? Or will alternatives like TCR-based cell therapy or multivalent antibody-T cell engagers leave them in the dust?
New checkpoint inhibitor on the block
Researchers at Austrian IMBA have identified a well-known co-factor of amino acid synthesis and monoamine neurotransmitter synthesis to play a prominent role in the development of autoimmunity and cancer.
BIO-Europe: advanced therapies in focus
Gene and cell therapies, pediatric drugs, and formulation were just some hot topics discussed in a record number of B2B meetings at BIO-Europe in Copenhagen.